Osteopontin, intrinsic tissue regulator of intractable inflammatory diseases

Pathology International

Volumn 61, Issue 5, 2011, Pages 265-280

  Uede, Toshimitsu ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Integrin; Matricellular protein; Osteopontin; Syndecan 4; Tenascin c; Thrombin cleavage

Indexed keywords

ALPHA INTERFERON; INTEGRIN RECEPTOR; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; OSTEOPONTIN; SCLEROPROTEIN; SMALL INTERFERING RNA; STROMAL CELL DERIVED FACTOR 1; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; TRANSFORMING GROWTH FACTOR BETA;

AUTOIMMUNE DISEASE; CELL ADHESION; CELL MOTILITY; CYTOKINE PRODUCTION; HEPATITIS; HUMAN; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; REVIEW; TH1 CELL; TH17 CELL;

ANIMALS; AUTOIMMUNE DISEASES; DENDRITIC CELLS; EXTRACELLULAR MATRIX; HUMANS; INFLAMMATION; INTEGRINS; MICE; MUTATION; OSTEOPONTIN; PROTEIN ISOFORMS; SIGNAL TRANSDUCTION; TENASCIN; TH1 CELLS; TH17 CELLS;

EID: 79955029805     PISSN: 13205463     EISSN: 14401827     Source Type: Journal    
DOI: 10.1111/j.1440-1827.2011.02649.x     Document Type: Review

References (96)

1. Oldberg A, Franzen A, Heinegard D, Pierschbacher M, Ruoslahti E. Identification of a bone sialoprotein receptor in osteosarcoma cells. J Biol Chem 1988; 263: 19433-6.
2. Oldberg A, Franzen A, Heinegard D. Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc Natl Acad Sci U S A 1986; 83: 8819-23.
3. Sage EH, Bornstein P. Extracellular proteins that modulate cell-matrix interactions: SPARC, tenascin, thrombospondin. J Biol Chem 1991; 266: 14831-4.
4. Bornstein P. Diversity of function is inherent in matricellular proteins: An appraisal of thrombospondin 1. J Cell Biol 1995; 130: 503-6.
5. Murphy-Ullrich JE. The de-adhesive activity of matricellular proteins: Is intermediate cell adhesion an adaptive state? J Clin Invest 2001; 107: 785-90.
6. Imanaka-Yoshida K, Hiroe M, Nishikawa T etal. Tenascin-C modulates adhesion of cardiomyocytes to extracellular matrix during tissue remodeling after myocardial infarction. Lab Invest 2001; 81: 1015-24.
7. Bornstein P, Sage E. Matricellular proteins: Extracellular modulators of cell function. Curr Opin Cell Biol 2002; 14: 608-16.
8. Patarca R, Freeman GJ, Singh RP etal. Structural and functional studies of the early T lymphocyte activation 1 (Eta-1) gene. Definition of a novel T cell-dependent response associated with genetic resistance to bacterial infection. J Exp Med 1989; 170: 145-61.
9. Singh RP, Patarca R, Schwartz J, Singh P, Cantor H. Definition of a specific interaction between the early T lymphocyte activation 1 (Eta-1) protein and murine macrophatges in vitro and its effect upon macrophages in vivo. J Exp Med 1990; 171: 1931-42.
10. Patarca R, Saavedra RA, Cantor H. Molecular and cellular basis of genetic resistance to bacterial infection: The role of the early T-lymphocyte activation-1/osteopontin gene. Crit Rev Immunol 1993; 13: 225-46.
11. Mori K, Kobayashi S, Inobe M etal. In vivo cytokine gene expression in various T cell subsets of the autoimmune MRL/Mp-lpr/lpr mouse. Autoimmunity 1994; 17: 49-57.
12. Katagiri Y, Mori K, Hara T, Tanaka K, Murakami M, Uede T. Functional analysis of the osteopontin molecule. Ann N Y Acad Sci 1995; 760: 371-4.
13. Nau GJ, Chupp GL, Emile JF etal. Osteopontin expression correlates with clinical outcome in patients with mycobacterial infection. Am J Pathol 2000; 157: 37-42.
14. Nau GJ, Liaw L, Chupp GL, Berman JS, Hogan BL, Young RA. Attenuated host resistance against Mycobacterium bovis BCG infection in mice lacking osteopontin. Infect Immun 1999; 67: 4223-30.
15. Ashkar S, Weber GF, Panoutsakopoulou V etal. Eta-1 (osteopontin): An early component of type-1 (cell-mediated) immunity. Science 2000; 287: 860-64.
16. Chabas D, Baranzini SE, Mitchell D etal. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 2001; 294: 1731-5.
17. Jansson M, Panoutsakopoulou V, Baker J, Klein L, Cantor H. Cutting edge: Attenuated experimental autoimmune encephalomyelitis in eta-1/osteopontin-deficient mice. J Immunol 2002; 168: 2096-9.
18. Weiss JM, Renkl AC, Maier CS etal. Osteopontin is involved in the initiation of cutaneous contact hypersensitivity by inducing Langerhans and dendritic cell migration to lymph nodes. J Exp Med 2001; 194: 1219-29.
19. Lampe MA, Patarca R, Iregui MV, Cantor H. Polyclonal B cell activation by the Eta-1 cytokine and the development of systemic autoimmune disease. J Immunol 1991; 147: 2902-6.
20. Nau GJ, Guilfoile P, Chupp GL etal. A chemoattractant cytokine associated with granulomas in tuberculosis and silicosis. Proc Natl Aca Sci U S A 1997; 94: 6414-19.
21. O'Regan AW, Chupp GL, Lowry JA, Goetschkes M, Mulligan N, Berman JS. Osteopontin is associated with T cells in sarcoid granulomas and has T cell adhesive and cytokine-like properties in vitro. J Immunol 1999; 67: 1024-31.
22. Kouguchi Y, Kawakami K, Kon S etal. Penicillium marneffei causes osteopontin-mediated production of inteleukin-12 by peripheral blood mononuclear cells. Infect Immun 2002; 70: 1042-8.
23. Yamamoto N, Sakai F, Kon S etal. Essential role of the cryptic epitope SLAYGLR within osteopontin in a murine model of rheumatoid arthritis. J Clin Invest 2003; 112: 181-8.
24. Hamilton DW. Functional role of periostin in development and wound repair: Implications for connective tissue disease. J Cell Commun Signal 2008; 2: 9-17.
25. Kuznetsova SA, Roberts DD. Functional regulation of T lymphocytes by modulatory extracellular matrix proteins. Int J Biochem Cell Biol 2004; 36: 1126-34.
26. Shinohara ML, Lu L, Bu J etal. Osteopontin expression is essential for interferon-alpha production by plasmacytoid dendritic cells. Nat Immunol 2006; 7: 498-506.
27. Shinohara ML, Kim HJ, Kin JH, Garcia VA, Cantor H. Alternative translation of osteopontin generates intracellular and secreted isoforms that mediate distinct activities in dendritic cells. Proc Natl Acad Sci U S A 2008; 105: 7235-9.
28. Cantor H, Shinohara ML. Regulation of T-helper-cell lineage development by osteopontin: The inside story. Nat Rev Immunol 2009; 9: 137-41.
29. Shinohara ML, Kim JH, Garcia VA, Cantor H. Engagement of the type I interferon receptor on dendritic cells inhibits T helper 17 cell development: Role of intracellular osteopontin. Immunity 2008; 29: 68-78.
30. Barry ST, Ludbrook SB, Murrison E, Horgan CM. A regulated interaction between alpha5beta1 integrin and osteopontin. Biochem Biophys Res Commun 2000; 267: 764-9.
31. Hu DD, Lin EC, Kovach NL, Hoyer JR, Smith JW. A biochemical characterization of the binding of osteopontin to integrins alpha v beta 1 and alpha v beta 5. J Biol Chem 1995; 270: 26232-8.
32. Liaw L, Skinner MP, Raines EW etal. The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. Role of alpha v beta 3 in smooth muscle cell migration to osteopontin in vitro. J Clin Invest 1995; 95: 713-24.
33. Senger DR, Perruzzi CA, Papadopoulos-Sergiou A, Van de Water L. Adhesive properties of osteopontin: Regulation by a naturally occurring thrombin-cleavage in close proximity to the GRGDS cell-binding domain. Mol Biol Cell 1994; 54: 565-74.
34. Denhardt DT, Guo X. Osteopontin: An protein with diverse function. FASEB J 1993; 7: 1475-82.
35. Uede T, Katagiri Y, Iizuka J, Murakami M. Osteopontin, a coordinator of hose defense system: A cytokine or an extracellular adhesive protein? Microbiol Immunol 1997; 41: 641-8.
36. Christensen B, Schack L, Klaning E, Sorensen ES. Osteopontin is cleaved at multiple sites close to its integrin-binding motifs in milk and is a novel substrate for plasmin and cathepsin D. J Biol Chem 2010; 285: 7929-37.
37. Barry ST, Ludbrook SB, Murrison E, Horgan CM. Analysis of the alpha4beta1 integrin-osteopontin interaction. Exp Cell Res 2000; 258: 342-51.
38. Green PM, Ludbrook SB, Miller DD, Horgan CM, Barry ST. Structural elements of the osteopontin SVVYGLR motif important for the interaction with alpha(4) integrins. FEBS Lett 2001; 503: 75-9.
39. Smith LL, Cheumg HK, Ling LE etal. Osteopontin N-terminal domain contains a cryptic adhesive sequence recognized by alpha9beta1 integrin. J Biol Chem 1996; 271: 28485-91.
40. Morales-Ducret J, Wayner E, Elices MJ, Alvaro-Gracia JM, Zvaifler NJ, Firestein GS. α4/β1 integrin (VLA-4) ligands in arthritis: Vascular cell adhesion molecule-1 expression in synovium and on fibroblast-like synoviocytes. J Immunol 1992; 149: 1424-31.
41. Agnihotri R, Crawford HC, Haro H, Matrisian LM, Havrda MC, Liaw L. Osteopontin, a novel substrate for matrix metalloproteinase-3 (stromelysin-1) and matrix metalloproteinase-7 (matrilysin). J Biol Chem 2001; 276: 28261-7.
42. Yokosaki Y, Matsuura N, Sasaki T etal. The integrin alpha(9)beta(1) binds to a novel recognition sequence (SVVYGLR) in the thrombin-cleaved amino-terminal fragment of osteopontin. J Biol Chem 1999; 274: 36328-34.
43. Gao YA, Agnihotri R, Vary CP, Liaw L. Expression and characterization of recombinant osteopontin peptides representing matrix metalloproteinase proteolytic fragments. Matrix Biol 2004; 23: 457-66.
44. Ito K, Kon S, Nakayama Y etal. The differential amino acid requirement within osteopontin in alpha4 and alpha9 integrinmediated cell binding and migration. Matrix Biol 2009; 28: 111-19.
45. Myles T, Nishimura T, Yun TH etal. Thrombin activable fibrinolysis inhibitor, a potential regulator of vascular inflammation. J Biol Chem 2003; 278: 51059-67.
46. Weber GF, Ashkar S, Glimcher MJ, Cantor H. Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science 1996; 271: 509-12.
47. Katagiri YU, Sleeman J, Fujii H etal. CD44 variants but not CD44s cooperate with beta1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis. Cancer Res 1999; 59: 219-26.
48. Kon S, Ikesue M, Kimura C etal. Syndecan-4 protects against osteopontin-mediated acute hepatic injury by masking functional domains of osteopontin. J Exp Med 2008; 205: 25-33.
49. Senger DR, Wirth DF, Hynes RO. Tranformed mammalian cells secrete specific proteins and phosphoproteins. Cell 1979; 16: 885-93.
50. Behrend EI, Craig AM, Wilson SM, Denhardt DT, Chambers AF. Reduced malignancy of ras-transformed NIH3T3 cells expressing anti-sense osteopontin RNA. Cancer Res 1994; 54: 832-7.
51. Seier AM, Renkl AC, Schulz G etal. Antigen-specific induction of osteopontin contributes to the chronification of allergic contact dermatitis. Am J Pathol 2009; 176: 246-58.
52. Petrow PK, Hummel KM, Schedel J etal. Expression of osteopontin messenger RNA and protein in rheumatoid arthritis: Effects of osteopontin on the release of collagenase 1 from articular chondrocytes and synovial fibroblasts. Arthritis Rheum 2000; 43: 1597-605.
53. Yumoto K, Ishijima M, Rittling SR etal. Osteopontin deficiency protects joints against destruction in anti-type II collagen antibodyinduced arthritis in mice. Proc Natl Acad Sci U S A 2002; 99: 4556-61.
54. Ihara H, Denhardt DT, Furuya K etal. Parathyroid hormoneinduced bone resorption does not occur in the absence of osteopontin. J Biol Chem 2001; 276: 13065-71.
55. Ohshima S, Kobayashi H, Yamaguchi N etal. Expression of osteopontin at sites of bone erosion in a murine experimental arthritis model of collagen-induced arthritis: Possible involvement of osteopontin in bone destruction in arthritis. Arthritis Rheum 2002; 46: 1094-101.
56. Yamamoto N, Nakashima T, Torikai M etal. Successful treatment of collagen-induced arthritis in non-human primates by chimeric anti-osteopontin antibody. Int Immunopharmacol 2007; 7: 1460-70.
57. Fan K, Dai J, Wang H etal. Treatment of collagen-induced arthritis with an anti-osteopontin monoclonal antibody through promotion of apoptosis of both murine and human activated T cells. Arthritis Rheum 2008; 58: 2041-52.
58. Kanayama M, Kurotaki D, Morimoto J etal. Alpha9 integrin and its ligands constitute critical joint microenvironments for development of autoimmune arthritis. J Immunol 2009; 182: 8015-25.
59. Sato T, Nakai T, Tamura N etal. Osteopontin/Eta-1 upregulated in Crohn's disease regulates the Th1 immune response. Gut 2005; 54: 1254-62.
60. Diao H, Kon S, Iwabuchi K etal. Osteopontin as a mediator of NKT cell function in T cell-mediated liver diseases. Immunity 2004; 21: 539-50.
61. Tanaka K, Morimoto J, Kon S etal. Effect of osteopontin alleles on beta-glucan-induced granuloma formation in the mouse liver. Am J Pathol 2004; 164: 567-75.
62. Morimoto J, Inobe M, Kimura C etal. Osteopontin affects the persistence of beta-glucan-induced hepatic granuloma formation and tissue injury through two distinct mechanisms. Int Immunol 2004; 16: 477-88.
63. Saito Y, Kon S, Fujiwara Y etal. Osteopontin small interfering RNA protects mice from fulminant hepatitis. Hum Gene Ther 2007; 18: 1205-14.
64. Kitamura M, Iwabuchi K, Kitaichi N etal. Osteopontin aggravates experimental autoimmune uveoretinitis in mice. J Immunol 2007; 178: 6567-72.
65. Hikita ST, Vistica BP, Jones HR etal. Osteopontin is proinflammatory in experimental autoimmune uveitis. Invest Ophthalmol Vis Sci 2006; 47: 4435-43.
66. Inomata S, Shijubo N, Kon S etal. Circulating interleukin-18 and osteopontin are useful to evaluate disease activity in patients with tuberculosis. Cytokine 2005; 30: 203-11.
67. Maeda K, Takahashi K, Takahashi F etal. Distinct roles of osteopontin fragments in the development of the pulmonary involvement in sarcoidosis. Lung 2001; 179: 279-91.
68. Hirota S, Imakita M, Kohri K etal. Expression of osteopontin messenger RNA by macrophages in atherosclerotic plaques. A possible association with calcification. Am J Pathol 1993; 143: 1003-8.
69. Giachelli CM, Bae N, Almeida M, Denhardt DT, Alpers CE, Schwartz SM. Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J Clin Invest 1993; 92: 1686-96.
70. Ikeda T, Shirasawa T, Esaki Y, Yoshiki S, Hirokawa K. Osteopontin mRNA is expressed by smooth muscle-derived foam cells in human atherosclerotic lesions of the aorta. J Clin Invest 1993; 92: 2814-20.
71. O'Brien ER, Garvin MR, Stewart DK etal. Osteopontin is synthesized by macrophage, smooth muscle, and endothelial cells in primary and restenotic human coronary atherosclerotic plaques. Arterioscler Thromb 1994; 14: 1648-56.
72. Chiba S, Okamoto H, Kon S etal. Development of atherosclerosis in osteopontin transgenic mice. Heart Vessels 2002; 16: 111-17.
73. Matsui Y, Rittling SR, Okamoto H etal. Osteopontin deficiency attenuates atherosclerosis in female apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2003; 23: 1029-34.
74. Isoda K, Nishikawa K, Kamezawa Y etal. Osteopontin plays an important role in the development of medial thickening and neointimal formation. Circ Res 2002; 91: 77-82.
75. Liaw L, Lombardi DM, Almeida MM, Schwartz SM, deBlois D, Giachelli CM. Neutralizing antibodies directed against osteopontin inhibit rat carotid neointimal thickening after endothelial denudation. Arterioscler Thromb Vasc Biol 1997; 17: 188-93.
76. Singhal H, Bautista DS, Tonkin KS etal. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res 1997; 3: 605-11.
77. Ohshima S, Yamaguchi N, Nishioka K etal. Enhanced production of osteopontin in rheumatoid joints. J Rheumatol 2002; 29: 2061-7.
78. Take Y, Nakata K, Hashimoto J etal. Specifically modified osteopontin in rheumatoid arthritis fibroblast-like synoviocytes supports interation with B cells and enhances production of interleukin-6. Arthritis Rheum 2009; 60: 3591-601.
79. Jono S, Peinada C, Giachelli CM. Phosphorylation of osteopontin is required for inhibition of vascular smooth muscle cell calcification. J Biol Chem 2000; 275: 20197-203.
80. Ek-Rylander B, Andersson G. Osteoclast migration on phosphorylated osteopontin is regulated by endogenous tartrate-resistanacid phosphatase. Exp Cell Res 2010; 316: 443-51.
81. Ramaiah SK, Rittling S. Pathophysiological role of osteopontin in hepatic inflammation, toxicity, and cancer. Toxicol Sci 2008; 103: 4-13.
82. Takeda K, Hayakawa Y, Van Kaer L, Matsuda H, Yagita H, Okumura K. Critical contribution of liver natural killer T cells to a murine model of hepatitis. Proc Natl Acad Sci U S A 2000; 97: 5498-503.
83. Taylor KR, Gallo RL. Glycosaminiglycans and their proteoglycans:Host-associated molecular patterns for initiation and modulation of inflammation. FASEB J 2006; 20: 9-22.
84. Echtermeyer F, Streit M, Wilcox-Adelman S etal. Delayed wound repair and impaired angiogenesis in mice lacking syndecan-4. J Clin Invest 2001; 107: R9-R14.
85. Ishiguro K, Kadomatsu K, Kojima T etal. Syndecan-4 deficiency leads to high mortality of lipopolysaccharide-injected mice. J Biol Chem 2001; 276: 47483-8.
86. Midwood KS, Valenick LV, Hsia HC, Schwarzbauer JE. Coregulation of fibronectin signaling and matrix contraction by tenascin-C and syndecan-4. Mol Biol Cell 2004; 15: 5670-77.
87. Ruoslahti E. Integrins. J Clin Invest 1991; 87: 1-5.
88. Hynes RO. Integrins: Versatility, modulation, and signaling in celladhesion. Cell 1992; 69: 11-25.
89. Marcinkiewics C, Takaoka Y, Yokosaki Y etal. Inhibitory effects of MLDG-containing heterodimeric disintegrins reveal distinct structural requirements for interaction of the integrin alpha9beta1 with VCAM-1, tenascin-C, and osteopontin. J Biol Chem 2000; 275: 31930-37.
90. Eto K, Puzon-Mclaughlin W, Sheppard D, Sehara-Fujisawa A, Zhang XP, Takada Y. RGD-independent binding of integrin alpha9beta1 to the ADAM-12 and -15 disintegrin domains mediates cell-cell interaction. J Biol Chem 2000; 275: 34922-30.
91. Shinde AV, Bystroff C, Wang C etal. Identification of the peptide sequences within the EIIIA(EDA) segment of fibronectin that mediate integrin alpha9beta1-dependent cellular activities. J Biol Chem 2008; 283: 2858-70.
92. Vlahakis NE, Young BA, Atakilit A, Sheppard D. The lymphangiogenic vascular endothelial growth factors VEGF-C and -D are ligands for the integrin alpha9beta1. J Biol Chem 2005; 280: 4544-52.
93. Miller DH, Khan OA, Sheremata WA etal. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003; 348: 15-23.
94. Tubridy N, Behan PO, Capildeo R etal. The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology 1999; 53: 466-72.
95. O'Connor PW, Goodman A, Willmer-Hulme AJ etal. Randomized multicenter trial of natalizumab in acute MS relapses: Clinical and MRI effects. Neurology 2004; 62: 2038-43.
96. Vogt MH, Lopatinskaya L, Smits M, Polman CH, Nagelkerken L. Elevated osteopontin levels in active relapsing-remitting multiple sclerosis. Ann Neurol 2003; 53: 819-22.